These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16925750)

  • 41. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy.
    Mouraviev V; Sun L; Madden JF; Mayes JM; Moul JW; Polascik TJ
    Urology; 2007 Dec; 70(6):1141-5. PubMed ID: 18158035
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response.
    Alexander BM; Chen MH; Carroll P; D'Amico AV
    Urology; 2007 Aug; 70(2):320-3. PubMed ID: 17826497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
    Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
    Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficiency of ultrasensitive prostate-specific antigen assay in diagnosing biochemical failure after radical prostatectomy.
    Shimizu F; Tanaka S; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
    Jpn J Clin Oncol; 2007 Jun; 37(6):446-51. PubMed ID: 17656483
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?
    Caire AA; Sun L; Ode O; Stackhouse DA; Maloney K; Donatucci C; Mouraviev V; Polascik TJ; Robertson CN; Albala DM; Moul JW
    Urology; 2009 Sep; 74(3):643-7. PubMed ID: 19501891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients.
    Cozzarini C; Montorsi F; Fiorino C; Alongi F; Bolognesi A; Da Pozzo LF; Guazzoni G; Freschi M; Roscigno M; Scattoni V; Rigatti P; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):966-74. PubMed ID: 19619960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Diagnostic methodology for the biochemical recurrence of prostate cancer after radical prostatectomy].
    Serra AC; Narbón ES
    Arch Esp Urol; 2006 Dec; 59(10):1041-52. PubMed ID: 17283717
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
    Berger AP; Deibl M; Strasak A; Bektic J; Pelzer A; Steiner H; Spranger R; Fritsche G; Bartsch G; Horninger W
    Urology; 2006 Nov; 68(5):1067-71. PubMed ID: 17095070
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure.
    Haese A; Huland E; Graefen M; Huland H
    Anticancer Res; 1999; 19(4A):2641-4. PubMed ID: 10470210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy.
    Ellinger J; Müller SC; Wernert N; von Ruecker A; Bastian PJ
    BJU Int; 2008 Aug; 102(5):628-32. PubMed ID: 18410441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complexed prostate-specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy.
    Parsons JK; Partin AW; Trock B; Bruzek DJ; Cheli C; Sokoll LJ
    BJU Int; 2007 Apr; 99(4):758-61. PubMed ID: 17378839
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Post-treatment PSA, indicator of radical treatment effectiveness of localized cancer of the prostate].
    Ravery V; Hermieu JF; Hoffmann P; Delmas V; Boccon-Gibod L
    Prog Urol; 1996 Dec; 6(6):981-6. PubMed ID: 9235189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience.
    Siddiqui SA; Mynderse LA; Zincke H; Hoffmann NE; Lobo JR; Wilson TM; Kawashima A; Davis BJ; Blute ML
    Urology; 2007 Jul; 70(1):80-5. PubMed ID: 17656213
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lymphovascular invasion is an independent predictor of prostate-specific antigen failure after radical prostatectomy in patients with pT3aN0 prostate cancer.
    Yamamoto S; Kawakami S; Yonese J; Fujii Y; Ohkubo Y; Suyama T; Komai Y; Kijima T; Ishikawa Y; Fukui I
    Int J Urol; 2008 Oct; 15(10):895-9. PubMed ID: 18721204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
    Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
    Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
    BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.
    Rouprêt M; Hupertan V; Comperat E; Drouin SJ; Phé V; Xylinas E; Demanse D; Sibony M; Richard F; Cussenot O
    BJU Int; 2009 Sep; 104(6):813-7; discussion 817-8. PubMed ID: 19254280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.